On October 11, 2017 OncoSec Medical Incorporated (“OncoSec”) (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, reprted that they will present updated clinical data from its phase 2 Investigator Sponsored Trial assessing the combination of OncoSec’s investigational therapy, ImmunoPulse IL-12 (intratumoral pIL-12 [tavokinogene telseplasmid or “tavo”] with electroporation), and the approved anti-PD-1 therapy pembrolizumab, in patients with unresectable metastatic melanoma (Press release, OncoSec Medical, OCT 11, 2017, View Source [SID1234520860]). The late-breaking poster presentation will occur at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (“SITC”) 32nd Annual Meeting to be held on November 8-12, 2017, in National Harbor, MD. In addition, OncoSec will present preclinical data from its novel multi-gene expression platform termed PIIM (Polycistronic Interleukin-12 Immune Modulator) as a poster presentation at the same meeting.

“We are pleased that the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) will highlight updated clinical data from our phase 2 study that led us to initiate our global, open-label, registration directed phase 2b clinical trial, PISCES/KEYNOTE-695, which will evaluate the combination of ImmunoPulse IL-12 and pembrolizumab in metastatic melanoma patients who are progressing or have progressed on anti-PD-1,” said Punit Dhillon, CEO and President at OncoSec. “We remain committed to excelling in scientific innovation and clinical development and look forward to sharing data from our recently initiated study in mid-2018.”

The late-breaking poster presentation details are as follows:

Title: Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (pIL-12) plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1

Poster Number: P524

Lead Author: Alain Algazi, MD, Associate Professor, Department of Medicine (Hematology/Oncology), UCSF

Date and Time: Saturday, November 11th, 12:30-2:00 p.m. and 6:30-8:00 p.m.

Location: Gaylord National Resort & Convention Center

For more information about this trial, please visit:
View Source

The poster presentation details are as follows:

Title: Intratumoral administration of a multigene construct by electroporation can effectively modulate anti-tumor response in a murine B16.F10 model

Poster Number: P403

Lead Author: Shawna Shirley, Ph.D., Senior Scientist, OncoSec

Session Title: Oncolytic Viruses and Intratumoral Therapies

Date and Time: Friday, November 10th, 12:30-2:00 p.m. and 6:30-8:00 p.m.

Location: Gaylord National Resort & Convention Center

Per SITC (Free SITC Whitepaper) guidelines, abstracts are embargoed until 8:00 a.m. EST on November 7, 2017. To view abstracts, please visit the SITC (Free SITC Whitepaper) website at View Source

ImmunoPulse is a registered trademark of OncoSec Medical Incorporated, San Diego, CA, USA.

About the SITC (Free SITC Whitepaper) Annual Meeting
The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) is a non-profit medical professional society of influential scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Currently, SITC (Free SITC Whitepaper) has nearly 1,600 members representing 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer. The 32nd SITC (Free SITC Whitepaper) Annual Meeting & Associated Programs will take place November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, MD. For more information, please go to View Source

About PISCES (Anti-PD-1 IL-12 Stage III/IV Combination Electroporation Study)
PISCES is a global, multicenter phase 2b, open-label trial of intratumoral plasma encoded IL-12 (tavokinogene telseplasmid or “tavo”) delivered by electroporation in combination with intravenous pembrolizumab in patients with stage III/IV melanoma who have progressed or are progressing on either pembrolizumab or nivolumab treatment. The Simon 2-stage study of intratumoral tavo plus electroporation in combination with pembrolizumab will enroll approximately 48 patients with histological diagnosis of melanoma with progressive locally advanced or metastatic disease defined as Stage III or Stage IV. The primary endpoint will be the Best Overall Response Rate (BORR).

On October, 11, 2017 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that six abstracts, including one late-breaking abstract highlighting its TIL therapy, will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 32nd Annual Meeting from November 8-12, 2017 in National Harbor, Maryland (Press release, Iovance Biotherapeutics, OCT 11, 2017, View Source [SID1234520859]).

The late-breaking abstract titles are listed on the conference website at View Source

The other SITC (Free SITC Whitepaper) abstract titles are listed on the conference website under General Categories at View Source The details of the posters are as follows:

Cellular Therapy Approaches Late-Breaking Abstract

Title: Novel cryopreserved tumor infiltrating lymphocytes (LN-144) administered to patients with metastatic melanoma demonstrates efficacy and tolerability in a multicenter Phase 2 clinical trial
Authors: Sarnaik, et al.
Poster #: 515
Presentation date: Friday, November 10, 2017

Cellular Therapy Approaches Abstracts

Title: A Cryopreserved TIL Product, LN-144, Generated with an Abbreviated Method Suitable for High Throughput Commercial Manufacturing Exhibits Favorable Quality Attributes for Adoptive Cell Transfer
Authors: Wardell, et al.
Poster #: 203
Presentation date: Friday, November 10, 2017

Title: Studies of Key Quality Attributes for TIL Product, LN-144
Authors: Ritthipichai, et al.
Poster #: 194
Presentation date: Saturday, November 11, 2017

Immune Modulation, Cytokines, and Antibodies Abstract

Title: The T-cell Growth Factor Cocktail IL-2/IL-15/IL-21 Enhances Expansion and Effector Function of
Tumor-Infiltrating T cells in a Novel Process Developed by Iovance
Authors: Frank, et al.
Poster #: 357
Presentation date: Friday, November 10, 2017

Clinical Trials (In Progress) Abstracts

Title: A Phase 2 study to evaluate the safety and efficacy using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Authors: Leidner, et al.
Poster #: 221
Presentation date: Friday, November 10, 2017

Title: A Phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma
Authors: Jazaeri, et al.
Poster #: 220
Presentation date: Saturday, November 11, 2017

On October 11, 2017 Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, reported that the abstract featuring data from the Phase 1a/1b clinical trial evaluating the immunotherapy combination of its CSF-1R antibody, cabiralizumab (FPA008), with Opdivo (nivolumab), Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, has been selected for a late breaking oral presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 32nd Annual Meeting, being held Nov. 8-12, 2017 in National Harbor, Maryland (Press release, Five Prime Therapeutics, OCT 11, 2017, View Source [SID1234520858]).

Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Presentation
Session Name: Clinical Trials and Novel Combinations
Abstract Title: “First in Human Phase I Dose Escalation and Expansion of a novel combination, anti-CSF1-receptor (cabiralizumab) plus anti-PD-1 (nivolumab) in patients with advanced solid tumors.”
Session Date and Time: Saturday, Nov. 11, 2017, 3:30-6:00 PM EST
Presentation Time: 4:30-4:45 PM EST

This will be the first presentation of clinical data on a combination of a CSF-1R antibody and a checkpoint inhibitor, to the Company’s knowledge.

In the Phase 1a/1b trial, Five Prime and Bristol-Myers Squibb are evaluating the safety, tolerability and preliminary efficacy of the combination in advanced solid tumors. The presentation at the SITC (Free SITC Whitepaper) Annual Meeting will focus on preliminary safety, pharmacokinetic and pharmacodynamic data as well as initial efficacy data from one of the expansion cohorts.

On October 11, 2017 MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, reported the initiation of patient enrollment at a second site, Memorial Sloan Kettering Cancer Center (MSK), in a Phase 1 clinical trial evaluating a new radioimmunotherapy product for patients with locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies including colon and lung cancers (Press release, MabVax, OCT 11, 2017, View Source [SID1234520852]).

MVT-1075 (177Lu-CHX-A″-DTPA-HuMab-5B1) combines a potent radiotherapy with the tumor targeting specificity of the HuMab-5B1 antibody. Dr. Eileen O’Reilly, associate Director of the David M. Rubenstein Center for Pancreatic Cancer Research, attending physician, at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College is the lead investigator for the MVT-1075 Phase 1 clinical trial. The Company’s objective is now to enroll additional patients and report interim results before the end of the year.

“We are very excited to expand patient enrollment for this Phase 1 trial at MSK,” said David Hansen, MabVax President and CEO. “We are building on the very encouraging results from our Phase 1 clinical trials of the fully human monoclonal antibody MVT-5873, where we established safety and a maximum tolerated dose; and the Company’s PET imaging diagnostic product MVT-2163, in which we established safety, specificity and the dosing strategy which guides our radioimmunotherapy program. Together a total of 50 patients were treated setting the stage for clinical evaluation of MVT-1075, and we expect to announce topline interim data this quarter.”

On October 11, 2017 Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, reported that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company entitled “Beyond PARP – Next Generation DDR Therapeutics” at the 2017 BIO Investor Forum in San Francisco (Press release, Sierra Oncology, OCT 11, 2017, View Source [SID1234520850]).

The presentation is scheduled for 11:00 am PT on Tuesday, October 17th. A live audio webcast and archive of the presentation will be accessible through www.sierraoncology.com.